Drug intelligence / Profile preview

177Lu-PSMA I&T + 64Cu-PSMA I&T

Development stage: Unknown
Lead developer: Curium
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-PSMA I&T + 64Cu-PSMA I&T is a theranostic radiopharmaceutical program being developed by Curium in collaboration with PeptiDream and PDRadiopharma for the treatment and diagnosis of prostate cancer. The program consists of two complementary agents: 177Lu-PSMA-I&T (lutetium [177Lu] zadavotide guraxetan), a therapeutic radioligand labeled with the beta-emitting isotope Lutetium-177, and 64Cu-PSMA-I&T, a diagnostic PET imaging agent labeled with Copper-64. Both agents target the prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. The diagnostic agent is used to identify and stage PSMA-positive tumors, while the therapeutic agent delivers targeted radiation to destroy those cancer cells. The therapeutic agent is currently in Phase 3 development (ECLIPSE trial) for metastatic castration-resistant prostate cancer (mCRPC), and the diagnostic agent is in Phase 3 trials (SOLAR RECUR and SOLAR STAGE) for detecting and staging prostate cancer.

Other names: lutetium (177Lu) zadavotide guraxetancopper (64Cu) zadavotide guraxetan177Lu-PSMA I&T64Cu-PSMA I&T

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 177Lu-PSMA I&T + 64Cu-PSMA I&T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-PSMA I&T + 64Cu-PSMA I&T.

Explore the full profile